| Click for the Finfacts Ireland Portal Homepage |

Finfacts Business News Centre

Home 
 
 News
 Irish
 Irish Economy
 EU Economy
 US Economy
 UK Economy
 Global Economy
 International
 Property
 Innovation
 
 Analysis/Comment
 
 Asia Economy

RSS FEED


How to use our RSS feed

 
Web Finfacts

See Search Box lower down this column for searches of Finfacts news pages. Where there may be the odd special character missing from an older page, it's a problem that developed when Interactive Tools upgraded to a new content management system.

Welcome

Finfacts is Ireland's leading business information site and you are in its business news section.

Links

Finfacts Homepage

Irish Share Prices

Euribor Daily Rates

Irish Economy

Global Income Per Capita

Global Cost of Living

Irish Tax - Income/Corporate

Global News

Bloomberg News

CNN Money

Cnet Tech News

Newspapers

Irish Independent

Irish Times

Irish Examiner

New York Times

Financial Times

Technology News

 

Feedback

 

Content Management by interactivetools.com.

News : Global Economy Last Updated: Aug 24, 2010 - 4:49:58 PM


Pharmaceutical Industry: Proportion of sales from newer drugs drops; $65bn spent in US on R&D in 2009; 200,000 jobs to go in 2009-2015
By Michael Hennigan, Founder and Editor of Finfacts
Jun 28, 2010 - 9:35:30 PM

Email this article
 Printer friendly page

The pharmaceutical industry continues to rely heavily on sales from an ageing portfolio of drugs, whilst the proportion of total sales from newer drugs has dropped, according to data released Monday from the 2010 Pharmaceutical R&D Factbook complied by CMR International, a Thomson Reuters business. In 2009, over $65bn was spent in the US on R&D and 200,000 jobs will be cut in the industry in the US, Europe and Japan in the period 2009-2015.

The new edition of the R&D Factbook shows that the majority of sales for the world's leading pharmaceutical companies are derived from the most mature drugs, with the top three drugs for a company on average contributing 44 per cent of total sales.

A large number of patents that are due to expire over the next five years. As patents expire on blockbuster prescription tablets like Pfizer's $12bn-a-year cholesterol medicine Lipitor and AstraZeneca's $5bn heartburn pill Nexium, cut-price generics will rush in and slash margins. Between now and 2015 products with sales of more than $142bn will face copycat competition, according to IMS Health, a leading global supplier of prescription drug data. It is the biggest "cliff" of patent expiries in the history of the pharmaceuticals industry.

Reuters reported earlier this month that Big Pharma doesn't have nearly enough new drugs in the pipeline to replace all those it is about to lose. Since 1950 -- virtually the dawn of the modern era of medicine -- a total of 1,256 new drugs have been approved by the US Food and Drug Administration (FDA). But the industry today produces roughly the same number of new medicines that it did 60 years ago.

The Factbook says that more than $65bn was invested in R&D last year in the US alone but the number of new drugs launched annually has fallen 44 per cent since 1997.

A general decline in success rates for new drugs also has taken its toll on productivity and indicative of this is a doubling of phase III terminations in the period 2007-2009 compared with those in 2004-2006. Further analysis of the data reveals that less than 1 in 10 drugs reaching 'first toxicity dose' can now expect to be successfully launched.  

Key highlights from the 2010 R&D Factbook include:

  • The proportion of total sales from drugs launched within the last five years has dropped to below 7 per cent, compared with 8 per cent in 2008.  

  • R&D expenditure dropped by 0.3 per cent in 2009, down from 6.6 per cent in 2008, and in stark contrast to the growth rate of previous years.

  • 26 new molecular entities (NME) were launched onto the global market in 2009, an increase from 2008's 20-year low of 21.

  • 17.9 per cent of global R&D expenditure was allocated to anti-cancer drugs, making it the therapeutic area receiving the largest proportion of investment.

  • Competition from the generics sector is increasing in particular due to contributions from companies based in India and China.  

"The latest data shows that poor productivity in 2009 continued to be exasperated by the low success rate for drugs in late stage development and a decline in sales from new drugs launched within the last 5 years," said Hans Poulsen, head of consulting at CMR International. "The increase in NME launches compared with 2008 offers some positive news however, with data indicating a continued drop in overall success rates, it remains to be seen if the industry can reverse a 10 year trend in declining R&D output."

The information published in the Factbook is based on primary sources covering major pharmaceutical companies which account for approximately 80 per cent of the industry's global R&D expenditure.

More than 50% of Ireland's merchandise exports are from the pharmaceutical and medical devices sectors.

In the five years to 2009, exports increased by 26% but the payroll remained almost static at 40,000.

Sam Isaly, managing partner at OrbiMed Advisors -- which has some $5bn under management and is one of the world's largest healthcare investment firms -- told Reuters that he expects employment in the 14 Big Pharma companies across the United States, Europe and Japan to fall around 20 per cent between 2009 and 2015. That means some 200,000 jobs will disappear across the drugs business -- not only in research but also in sales and back office functions.

Is the pharma industry moving beyond blockbuster drugs? Alan Barge, head of oncology at AstraZeneca, discusses the issue with CNBC:

Pharmaceutical giant Pfizer is accused of pushing a pain pill, Bextra, to the masses and is forced to pay a total of $2.3 billion dollars in civil and criminal fines for its subsidiary, Pharmacia. The $1.3 billion dollar criminal fine is larger than any other case in US history:

Related Articles


© Copyright 2010 by Finfacts.com

Top of Page

Global Economy
Latest Headlines
The changing face of global banana trade
Investor confidence in global economic growth remains high
IMF Fiscal Monitor: Public debt ratios in advanced countries stabilise
IMF says recovery is becoming broader; Warns of low inflation in Eurozone
Emerging market output growth slows to marginal pace in March
Russia’s credit rating outlook cut; MICEX share index falls
US and UK residents hold 74% of private shares of Russian gas giant Gazprom
Emerging market growth slows further in 2014
Global manufacturing PMI hits 34-month high in February 2014
Swiss battle to avoid another UBS tax debacle
Russia would be vulnerable to tough economic sanctions
Switzerland to back OECD tax treaty
OECD: Faster job creation unlikely to return employment rates to pre-crisis levels
Alpine tax haven fears for its survival
Vienna world’s best city for expatriates; Dublin at 34 in list of 223 cities
Fund managers fear China hard landing; Optimism towards Europe at new highs
OECD says outlook for most advanced economies is improving
Capex spending by global companies forecast to fall in 2014
Growth engines struggle in emerging economies
Economic convergence is a myth in Europe and in emerging economies
Investors start 2014 more optimistic about global growth prospects
Davos 2014: Richest 85 people worth as much as 3.5bn poorest; Few poor countries by 2035
IMF projects global growth at 3.7% in 2014, rising to 3.9% in 2015
Davos 2014: World Economic Forum to cost $40,000 average per attendee
Stockbuilding main driver of OECD GDP growth in the third quarter of 2013
World Bank warns West's central banks not to imperil emerging market capital flows
Worldwide productivity growth weakened for the third straight year in 2013
Growth set to improve in most large economies in first half of 2014
In a crowded market, Swiss cheesemakers return to basics
Half world’s countries could depend on resource sector for growth in 20 years
Sub-Saharan Africa remains second-fastest-growing region in the world
Emerging markets growth slowed at the end of 2013
Global shares rose 20% in 2013; Nikkei best in 41 years, Dow in 18
Commodity prices down in 2013; Gold plunges; US dollar and euro rise
Corporate tax reform and the biggest tech tax havens
Tax: OECD seeks inspiration from FATCA model
IEA raises forecast for 2013 and 2014 global oil demand
Composite leading indicators suggest improving economic outlook in major economies
First global trade deal in decades to reduce trading costs
Emerging market growth strengthens in November